Abstract
A growing number of patients is treated with intrathecal application of autologous bone marrow cells (aBMCs), but clinical data are completely lacking in movement disorders. We provide first clinical data on efficacy and safety of this highly experimental treatment approach in parkinsonian syndromes.
Original language | English |
---|---|
Journal | Movement Disorders |
Volume | 27 |
Issue number | 12 |
Pages (from-to) | 1552-5 |
Number of pages | 4 |
ISSN | 0885-3185 |
DOIs | |
Publication status | Published - 2012 |